

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A method of attracting a leukocyte to a wound location or area of inflammation comprising the step of administering to the location or area a peptide selected from the group consisting of SEQ ID NOS: 1, 2, 5, 6, and 7.

2. (Currently Amended) The method of claim 1, wherein the peptide has at least 15 contiguous ~~nucleotides~~ amino acids how wfrom SEQ ID NO: 1.

3. (Canceled)

4. (Original) The method of claim 1, wherein the peptide has a length of less than 60 amino acid residues.

5. (Original) The method of claim 1, wherein the peptide is synthesized.

6. (Original) The method of claim 1, wherein the leukocyte is a mammalian leukocyte.

7. (Original) The method of claim 6, wherein the leukocyte is a porcine leukocyte.

8. (Original) The method of claim 1, wherein the leukocyte is a neutrophil.

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Currently Amended) A method of attracting a leukocyte to a wound location or area of inflammation within an organism through chemotaxis, said organism having an immune system including leukocytes therein, said method comprising the steps of:

administering a peptide to the organism, said peptide having from 15 to 39 amino acids and having therein at least 15 contiguous amino acids from SEQ ID NO: 1; and causing said leukocyte to migrate to said location or area.

13. (Previously Presented) The method of claim 12, said peptide being selected from the group consisting of SEQ ID NOS: 1, 2, 5, 6, and 7.

14. (Previously Presented) The method of claim 12, wherein the leukocyte is a mammalian leukocyte.

15. (Previously Presented) The method of claim 12, wherein the leukocyte is a porcine leukocyte.

16. (Previously Presented) The method of claim 12, wherein the leukocyte is a neutrophil.

17. (Previously Presented) The method of claim 12, wherein said peptide is synthetic.